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Abstract 25 
This article reviews the structures and biological activities of several classes of uridine-containing 26 
nucleoside antibiotics (tunicamycins, mureidomycins/pacidamycins/sansanmycins, 27 
liposidomycins/caprazamycins, muraymycins, capuramycins) that target translocase MraY on the 28 
peptidoglycan biosynthetic pathway. In particular, recent advances in structure-function studies, and 29 
recent X-ray crystal structures of translocase MraY complexed with muraymycin D2 and tunicamycin 30 
are described. The inhibition of other phospho-nucleotide transferase enzymes related to MraY by 31 
nucleoside antibiotics and analogues is also reviewed. 32 
 33 
Dedication. This article is part of a Special Issue commemorating Dr Kiyoshi Isono and his important 34 
contributions to the study of nucleoside antibiotics. Dr. Isono led the discovery of the liposidomycin 35 
 2 
natural products in 1985, one of the first studies in this field, which established that nucleoside 1 
antibiotics could be selective antibacterial agents. 2 
 3 
The discovery of the liposidomycin nucleoside antibiotics by Dr. Kiyoshi Isono and co-workers 4 
in 1985 [1], and the nucleoside antibiotic tunicamycin by Tamura and co-workers [2], has led to the 5 
identification and study of a related collection of uridine-containing nucleoside antibiotics with potent 6 
antibacterial activity, targetting the enzyme phospho-MurNAc-pentapeptide translocase (MraY) on the 7 
peptidoglycan cell wall biosynthetic pathway. The structures of each family have been reviewed in 8 
detail in reviews in 2003 [3] and 2010 [4]. This review will discuss recent structure-activity studies on 9 
each group of nucleoside antibiotics, and the mechanism of inhibition of translocase MraY, in 10 
particular, the recent crystal structures of nucleoside antibiotics bound to MraY. 11 
 12 
 13 
1. Antibacterial nucleoside antibiotics targetting bacterial peptidoglycan 14 
biosynthesis 15 
 16 
1.1 The tunicamycin group of GlcNAc-tunicamine nucleoside antibiotics (tunicamycins, 17 
streptovirudins, corynetoxins) 18 
The tunicamycin group of nucleoside antibiotics were isolated in 1971 from Streptomyces 19 
lysosuperficus by Tamara and co-workers [2]. They contain a uracil base attached to a C11 20 
tunicamine sugar, glycosylated at C11 by a GlcNAc sugar and N-acylated at C10 by a C12-C15 fatty 21 
acid (see Figure 1). They showed antibacterial activity against a range of Gram-positive bacteria, 22 
especially those in the Bacillus genus (MIC 0.1-20 µg/ml) [2], but also showed toxicity towards 23 
eukaryotic cells, due to inhibition of eukaryotic N-linked glycoprotein biosynthesis [5]. The 24 
streptovirudins and corynetoxins contain the same uracil-tunicamine skeleton, but are acylated by 25 
different fatty acids [3]. The biosynthetic gene cluster for the tunicamycin antibiotics has been 26 
identified in Streptomyces chartreusis [6], and the biosynthetic pathway has been shown to involve 27 
an unusual radical SAM enzyme TunM in the assembly of the tunicamine sugar [7].  28 
 29 
 3 
Figure 1. Structures of tunicamycins  1 
 2 
A total synthesis of tunicamycin V was reported in 2017 by Ichikawa and co-workers [8], 3 
which has enabled the synthesis of tunicamycin analogues for structure-activity study [9]. A lipid-4 
truncated analogue and an analogue lacking the GlcNAc sugar both lost 1000-fold in MraY 5 
inhibition activity but retained some enzyme inhibition, while an analogue lacking the nucleoside 6 
base was completely inactive [9]. The preseence of the uracil base has been shown to be required in 7 
other nucleoside antibiotic families [3,4], which can be rationalised by the MraY structural studies 8 
described in Section 2.2. 9 
 10 
1.2  The mureidomycin group of ureidyl-peptide nucleoside antibiotics (mureidomycins, 11 
pacidamycins, napsamycins, sansanmycins) 12 
 Mureidomycins A-D were isolated from Streptomyces flavidoviridens SANK 60486, and 13 
first reported in 1989 [10]. They showed potent antimicrobial activity against a range of 14 
Pseudomonas strains (MIC 0.1 – 3 µg/mL), and protected mice against infection by Pseudomonas 15 
aeruginosa (ED50 50 mg/kg for MrdC) [11,12]. Phospho-MurNAc-pentapeptide translocase (MraY) 16 
on the bacterial peptidoglycan biosynthetic pathway was identified as the molecular target of these 17 
compounds [11]. A closely related series of pacidamycins 1–7, isolated from Streptomyces 18 
coeruleorubidus strain AB 1183F-64, were also reported in 1989 [13-15]. The pacidamycins also 19 
showed antimicrobial activity against Pseudomonas strains (MIC’s 8 – 64 µg / mL), but they were 20 
found not to protect mice against infection by Pseudomonas aeruginosa [15].  21 
The structures of both families contain a 3’-deoxyuridine sugar attached via an 4’,5’-22 
enamide linkage to the carboxyl group of an N-methyl 2,3-diaminobutyric acid (DABA) residue, to 23 
which amino acids are attached on both nitrogen substituents (see Figure 2). To the -amino group 24 
of DABA is attached either Met (mureidomycins) or Ala (pacidamycins), which is in turn attached 25 
via a urea linkage to a C-terminal aromatic amino acid, either meta-tyrosine (mureidomycins), or 26 
Trp or Phe (pacidamycins). To the -amino group of the DABA residue is attached in most cases a 27 
meta-tyrosine residue, except in pacidamycin D, which contains Ala. Two further mureidomycins E 28 
and F were later reported, containing a bicylic derivative of meta-tyrosine at the amino-terminal 29 
position [16], also found in the closely related napsamycins, which were reported in 1994 [17]. The 30 
sansanmycins were reported in 2007, and contain the same structural sekeleton as the 31 
mureidomycins, but contain Trp at the C-terminal position, and contain either Met, Leu, or 32 
methionine sulfoxide at position 4 [18,19]. The sansanmycins showed antipseudomonal activity, 33 
but also showed activity against Mycobacterium tuberculosis (MIC 8-20 µg/ml) [19]. The structures 34 
of these classes of uridyl peptide antibiotics are shown in Figure 2. 35 
 4 
A series of synthetic dihydropacidamycin analogues in which the 4’-5’ enamide was absent 1 
were prepared by Microcide Inc. The parent 4R-dihydropacidamycin retained antipseudomonal 2 
activity, but with somewhat reduced MIC (64 µg/ml) compared to pacidamycin D [20]. Synthetic 3 
analogues containing Phe or Leu at position 4, and Trp or Tyr at position 5, showed best 4 
antipseudomonal activity (MIC 4-16 µg/ml) [20]. An analogue containing 4-fluorophenylalanine in 5 
place of Met at position 4 showed antimicrobial activity against clinical E. coli strains (MIC 4-8 6 
µg/ml), as well as Mycobacterium tuberculosis (MIC 4-10 µg/ml) [21]. In 2011, Okamoto et al 7 
published a total synthesis of pacidamycin D [22], which they have used to synthesise further 8 
analogues varying the N-terminal dipeptide chain [23]. They have reported that meta-tyrosine in the 9 
amino-terminal position is considerably more active than L-Tyr, and that the stereochemistry of the 10 
2,3-diaminobutyric acid is important for both MraY inhibition and antimicrobial activity [23]. 11 
 12 
Figure 2. Structural features of mureidomycin, pacidamycin, napsamycin, and sansanmycin families 13 
of ureidyl peptide antibiotics. Structural variation show by blue arrows, structure-activity 14 
observations shown by red arrows. 15 
 16 
 5 
The anti-TB activity of the sansanmycin series has been developed signifcantly by Payne 1 
and co-workers, via chemical synthesis of a set of dihydrosansanmycin analogues [24]. They found 2 
that dihydrosansamycin B had significantly improved anti-TB activity (MIC50 0.3 µM) compared 3 
with sansanmycin B (MIC50 9.5 µM). Structure-activity studies revealed that analogues containing 4 
glycine at the N-terminal amino acid showed comparable activity (MIC50 0.63 µM), and that a 5 
further modification of a cyclohexyl group at position 4 led to an analogue with MIC50 80 nM that 6 
was a potent MraY inhibitor (IC50 30 nM), as shown in Figure 3 [24]. 7 
 8 
Figure 3. Antimicrobial activity of synthetic dihydrosansanmycin analogues modified at positions 2 9 
and 4 against Mycobacterium tuberculosis H37Rv. 10 
 11 
The biosynthetic gene cluster for the pacidamycin antibiotics, containing a number of non-12 
ribosomal peptide synthetase genes, was identified in Streptomyces coeruleorubidus in 2010 by the 13 
groups of Goss [25] and Walsh [26]. The unusual ureidopeptide moiety at the carboxyl terminus of 14 
the peptide chain is assembled via carboxyl activation of Ala by PacN, followed by carboxylation, 15 
and then peptide bond formation catalysed by ligase PacL [27]. The diamino acid DABA is 16 
biosynthesised from L-threonine by a pyridoxal 5’-phosphate-dependent -replacement reaction, 17 
also observed for mureidomycin biosynthesis in Streptomyces flavidovirens [28], using L-aspartate 18 
as a nucleophile, followed by a -elimination reaction [26]. The modified uridine nucleoside is 19 
formed via oxidation of uridine to the 5’-aldehyde, followed by transamination to 5’-amino-uridine, 20 
followed dehydration of the 4’-hydroxyl group [29]. The crystal structure of the novel dehydratase 21 
enzyme Pac13 has been determined, implicating His-42 in the catalytic mechanism [30]. The 22 
additional N-terminal Ala found in some pacidamycins and mureidomycins is added by ligase 23 
PacB, that uses Ala-tRNA as an amino acid donor [31]. The unusual amino acid meta-tyrosine is 24 
 6 
biosynthesised from L-Phe by a novel non-heme iron- and tetrahydrobiopterin-dependent 1 
hydroxylase [32]. Mutasynthesis has been used to generate novel chlorinated pacidamycin 2 
derivatives [33], and modified sansanmycins [34]. The modified sansanmycins were reported to 3 
retain antimicrobial activity, in some cases with reduced activity, but MX-6 containing 4-4 
fluorophenylalanine at the C-terminus showed enhanced antimicrobial activity against B. subtilis 5 
and M. tuberculosis [34]. 6 
 7 
1.3 The liposidomycin group of liponucleoside antibiotics (liposidomycins, caprazamycins) 8 
 The liposidomycins are liponucleoside natural products containing an aminoglycoside 9 
sugar, which were reported by K. Isono and coworkers in 1985 [1], and their molecular structures 10 
reported in 1988 [35]. They show antimicrobial activity against Mycobacterium strains (MIC 1.6 11 
µg/ml) [1]. The caprazamycins were reported in 2003: they share the same structural skeleton as the 12 
liposidomycins, as shown in Figure 4, but the 3-methylglutaryl substituent is glycosylated by an 13 
additional L-rhamnose sugar [36,37]. 14 
 15 
Figure 4. Structures of the liposidomycins and caprazamycins, and synthetic analogues 16 
 17 
Synthetic uridine-based analogues of the liposidomycins containing the 18 
aminoribofuranoside sugar retain MraY inhibition activity (IC50 0.14-50 µM), but show weaker 19 
antimicrobial activity, demonstrating the importance of the lipophilic substituent, probably needed 20 
for cellular uptake [38-40]. Fer et al have published a further series of uridine-based analogues 21 
containing a lipophilic group linked via a triazole heterocycle, which show antimicrobial activity 22 
against Staphylococcus aureus, and inhibit MraY with IC50 values in the range 100-1000 µM [41]. 23 
Matsuda and coworkers have synthesised analogues of caprazamycin containing an alkyl chain in 24 
place of the glutarate diester sidechain, which retain antimicrobial activity but show enhanced 25 
stability [42]. A semisynthetic caprazamycin derivative CPZEN-45 is active in animal models for 26 
 7 
protection against tuberculosis infection, and Ichizaki et al published in 2013 that CPZEN-45 1 
inhibits transferase WecA in M. tuberculosis, involved in lipoloysaccharide biosynthesis, rather 2 
than MraY [43].  3 
 The biosynthetic gene cluster for production of the caprazamycins in Streptomyces sp. 4 
MK730-62F2 was identified in 2009 by Kaysser et al [44]. The biosynthetic pathway involves the 5 
formation of uridine 5’-aldehyde, followed by a pyridoxal-5’-phosphate dependent reaction with 6 
glycine to form a uridine-amino acid adduct, followed by an  S-adenosylmethionine-dependent 7 
reaction transferring a 3-amino-3-carboxypropyl group [44]. A gene deletion strain, in which cpz21 8 
encoding an acyltransferase enzyme acting late in the biosynthetic pathway had been deleted, was 9 
found to accumulate the caprazamycin aglycone [44]. The genes responsible for addition of the L-10 
rhamnose sugar found in caprazamycins have been identified, allowing the heterologous gene 11 
expression of intact caprazamycins [45]. The biosynthetic pathway for the aminoribosyl sugar 12 
moiety found in the caprazamycin, muraymycin and other nucleoside natural products has also been 13 
shown to proceed via uridine 5’-aldehyde, and was reported by van Lanen and co-workers [46-48].  14 
 15 
1.4  The muraymycin group of lipo-ureidylpeptide nucleoside antibiotics 16 
 The muraymycins were reported in 2002 by McDonald et al, isolated from a Streptomyces 17 
sp. strain [49]. Their structure contains an aminoribofuranoside monosaccharide attached to the 5’-18 
position of a uridine-amino acid, similar to that found in the liposidomycins & caprazamycins, as 19 
shown in Figure 5, and a ureidopeptide structure linked via a 3-aminopropyl moiety [49]. The 20 
muraymycins also target translocase MraY (IC50 0.027 µg/ml), show antimicrobial activity against 21 
strains of Staphylococcus aureus (MIC 2-16 µg/ml) and Enterococcus (MIC 16-64 µg/ml), and 22 
were reported to protect mice against S. aureus infection (ED50 1.1 mg/kg) [49].  23 
 24 
Figure 5. Structures of muraymycin antibiotics and synthetic analogues 25 
 8 
 1 
Several bioactive muraymycin analogues have been generated via total chemical synthesis. 2 
Tanino et al have synthesised analogues in which the hydroxyleucine residue is replaced by an 3 
alkyl sidechain, which show MraY inhibition activity (IC50 0.33 µM), and retain antimicrobial 4 
activity [50]. The same group have reported that the epicapreomycidine amino acid (a cyclic 5 
analogue of arginine) can be replaced by arginine, lysine or ornithine residues, and that these 6 
synthetic analogues retain antimicrobial activity [51].  Takeoka et al. have prepared further 7 
analogues with L-arginine in place of epicapreomycidine, in which the C-terminal amino acid is 8 
removed, which retain full MraY inhibition activity, and show enhanced antimicrobial activity 9 
against Pseudomonas strains [52]. Spork et al have synthesised an analogue of muraymycin lacking 10 
the aminoribose sugar which retains activity for MraY inhibition (IC50 2 µM) [53]. The -11 
guanylated fatty acid which is found in the most active muraymycins has been shown to assist 12 
localisation of the antibiotic into the cell membrane [54]. The total synthesis of muraymycin D1 13 
was reported in 2016 by Mitachi et al [55], enabling the synthesis of further analogues. The 14 
biosynthetic gene cluster for the biosynthesis of muraymycin in Streptomyces sp. NRRL 30471 was 15 
reported in 2011 [56]. 16 
  17 
1.5 The capuramycin group of caprolactam nucleoside antibiotics (capuramycin, A-500359A) 18 
 Capuramycin, a nucleoside antibiotic produced by Streptomyces griseus, containing a uronic 19 
acid monosaccharide attached to the 5’ position of a modified uridine nucleoside, to which is 20 
attached a 7-membered caprolactam ring, as shown in Figure 6, was first reported in 1986 [57,58]. 21 
Capuramycin and a methylated derivative A-500359A which shows antimicrobial activity against 22 
Mycobacterium smegmatis (MIC 2-16 µg/ml) and potent MraY inhibition (IC50 0.017 µg/ml) was 23 
then reported in 2003 [59,60]. A-500359E, which lacks the aminocaprolactam ring, shows potent 24 
inhibition of MraY (IC50 0.027 µM), but lacks antimicrobial activity [61]. Semi-synthetic 25 
derivatives of A-500359E have been reported, in which the aminocaprolactam is replaced by 26 
synthetic arylamines, which show potent MraY inhibition (IC50 10-40 ng/ml), and antimicrobial 27 
activity against Mycobacterium strains (MIC 0.5-2 µg/ml) [62]. Acylation of capuramycin on the 2’ 28 
hydroxyl group gave a further series of bioactive derivatives, including a decanoyl derivative which 29 
shows very potent activity against M. tuberculosis (MIC 0.06 µg/ml) [63]. 30 
 A biosynthetic gene cluster for a closely related capuramycin antibiotic A-503083B in 31 
Streptomyces sp. SANK 62799 was reported in 2010 [64]. The biosynthetic steps for attachment of 32 
a caprolactam moiety were elucidated, via carboxy methyltransferase CapS and transferase CapW 33 
[64]. The biosynthetic gene cluster for capuramycin A-102395 has also been reported, involving the 34 
incorporation of L-threonine into uridine 5’-carboxamide [65]. Transferase CapW has been used to 35 
 9 
prepare of a set of 43 semi-synthetic bioactive capuramycin derivatives [66]. Several of these 1 
analogues retained similar antimicrobial activity to the parent compound, with three analogues 2 
showing enhanced activity against M. smegmatis and M. tuberculosis [66]. 3 
 4 
 5 
Figure 6. Capuramycin natural products and synthetic analogues 6 
 7 
1.6 Comparison of antimicrobial activities of nucleoside natural products. 8 
The nucleoside natural product antibiotics show very interesting and varied antimicrobial 9 
activities. The mureidomycins show particularly potent antimicrobial activity against Pseudomonas 10 
aeruginosa (MIC 0.1 – 3 µg/mL), a bacterium responsible for antibiotic-resistant infections around 11 
the world, and can protect mice against infection by Pseudomonas aeruginosa [11,12]. The 12 
pacidamycins and napsamycins also show anti-pseudomonal activity, but synthetic 13 
dihydropacidamycins containing modifications at position 4 (see Figure 2) showed new 14 
antimicrobial  spectrum against Escherichia coli (MIC 4-8 µg/mL) and Citrobacter freundii (1.0 15 
µg/mL) [20,21]. Given that the MraY sequences from these organisms are quite closely related, it 16 
seems likely that these changes in antibacterial spectrum are caused by changes in uptake. 17 
The liposidomycin and caprazamycin liponucleosides ahow activity against strains of 18 
Mycobacterium (MIC 1.6 µg/ml) [2]. The synthetic caprazamycin derivative CPZEN-45 has shown 19 
efficacy against both drug-sensitive and extremely drug-resistant (XDR) Mtb in a mouse model of 20 
acute tuberculosis, and is in clinical trials against TB infection [43]. Capuramycins also show 21 
potent activity against Mycobacterium smegmatis (MIC 2-16 µg/ml) [59,60], and semi-synthetic 22 
derivatives show enhanced anti-Mtb activity [62,63]. The activity of the sansanmycins against 23 
Mycobacterium tuberculosis has been greatly enhanced in synthetic dihydrosansanmycins 24 
containing modifications at position 4 (MIC50 0.04-0.6 µM) [24].  25 
 10 
The muraymycin antibiotics show antimicrobial activity against Staphylococcus aureus (MIC 2-1 
16 µg/ml) and Enterococcus (MIC 16-64 µg/ml), and can protect mice against S. aureus infection 2 
[49]. Synthetic analogues containing two L-arginine residues show modified antimicrobial 3 
spectrum, notably against Pseudomonas strains (MIC 4-8 µg/mL) [52]. 4 
 5 
2. Mechanism of inhibition of translocase MraY by nucleoside antibiotics 6 
2.1  Kinetic mechanism of inhibition of translocase MraY 7 
 Translocase MraY catalyses the first step of the lipid cycle of bacterial peptidoglycan 8 
biosynthesis, namely the reaction of UDPMurNAc-L-Ala--D-Glu-m-DAP-D-Ala-D-Ala 9 
(UDPMurNAc-pentapeptide) with lipid carrier undecaprenyl phosphate, to form lipid intermediate 10 
1 (undecaprenyl-diphospho-MurNAc-pentapeptide), releasing uridine 5’-monophosphate (UMP) 11 
[67]. Translocase MraY is an integral membrane protein, shown to contain ten transmembrane 12 
helices [68]. The MraY-catalysed reaction is a phosphotransfer reaction, shown in Figure 7, whose 13 
catalytic mechanism could either proceed via a single step phosphotransfer, or a two-step 14 
mechanism involving an active site nucleophile [67]. Three aspartic acid residues in E. coli MraY 15 
(Asp-115, Asp-116, Asp-267), found on cytoplasmic loops, were shown to be essential for activity, 16 
and it has been proposed that two Asp residues bind the active site Mg2+ cofactor, while the third 17 
may be a catalytic nucleophile [69].  18 
 19 
 11 
 1 
Figure 7. Reaction catalysed by translocase MraY, showing MraY dimer structure and location of 2 
MraY active site. 3 
 4 
Mureidomycin A has been found to act as a slow-binding inhibitor (Ki 35 nM, Ki* 2 nM) for 5 
solubilised E. coli MraY, using a continuous fluorescnce enhancement assay, showing competitive 6 
enzyme inhibition towards both UDPMurNAc-pentapeptide and polyprenyl phosphate substrates 7 
[70]. Liposidomycin B also acts as a slow-binding inhibitor of E. coli MraY (Ki* 90 nM), showing 8 
non-competitive enzyme inhibition towards UDPMurNAc-pentapeptide, but competitive inhibition 9 
towards dodecaprenyl phosphate [71]. By contrast, tunicamycin is a reversible inhibitor of E. coli 10 
MraY (Ki 0.6 µM) showing competitive enzyme inhibition towards UDPMurNAc-pentapeptide, but 11 
non-competitive inhibition towards dodecaprenyl phosphate [71]. Muraymycin D2 and synthetic 12 
analogues thereof were found by Tanino et al to show competitive inhibition towards 13 
UDPMurNAc-pentapeptide (Ki 7.6 nM), but non-competitive inhibition versus undecaprenyl 14 
phosphate, against B. subtilis MraY using a radiochemical assay [51]. Hence there are some 15 
differences in the kinetic mechanism of MraY inhibition shown by the different classes of 16 
nucleoside antibiotics. 17 
The possibility that the mureidomycins might be mechanism-based inhibitors, reacting via 18 
the enamide functional group, which might be expected to be chemically reactive, has been found 19 
not to be the case, from studies on model enamide-containing analogues [72], and since synthetic 20 
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 12 
dihydropacidamycin and dihydrosansanmycin analogues retain MraY inhibition [20,21,24]. The 1 
observed slow-binding inhibition is therefore probably due to a conformational change in the 2 
protein structure, discussed in Section 2.2. Studies on analogues of mureidomycins have found that 3 
the amino terminus of the peptide chain and the N-methyl amide group of DABA are both 4 
important for MraY inhibition [73,74], leading to a proposal that the amino terminus might bind in 5 
place of the Mg2+ cofactor, positioned via a cis-amide rotamer in the peptide chain [74]. The amino 6 
group of the aminoribofuranose monosaccharide of liposidomycins and caprazamycins is also 7 
known to be important for activity [39]. 8 
 9 
2.2  Structure of Aquifex aeolicus MraY and its complexes with nucleoside antibiotics 10 
In 2013 the crystal structure of the Aquifex aeolicus MraY was determined, confirming the 11 
arrangement of ten transmembrane -helices [75]. The protein was found to crystallise as a dimer, 12 
with transmembrane helix 9 strongly bent and protruding into the membrane. The active site 13 
contained the three catalytic Asp residues, close to the Mg2+ cofactor, with Asp-265 positioned 14 
closest to the Mg2+ ion [75]. There is a triad of three histidine residues (His-324, His-325, His-326; 15 
HHH motif) conserved in bacterial sequences of the polyprenyl-phosphate N-acetylhexosamine 1-16 
phosphate transferase (PNPT) superfamily, which are positioned on loop E on the opposite side of 17 
the active site, 10-13 Å from the three catalytic Asp residues, shown in Figure 8. 18 
The structure of a complex of A. aeolicus MraY with muraymycin D2 was published in 19 
2016 [76]. Upon binding of muraymycin D2, transmembrane helix 9b (TM9b) moves away from 20 
the active site and the HHH motif (conserved across the PNPT family) in loop E extends, which 21 
widens and reshapes the active site, hence there is a significant conformational change upon ligand 22 
binding [76], which may be important for the catalytic cycle of MraY, and potentially could explain 23 
the slow-binding inhibition of MraY observed for some nucleoside natural product inhibitors 24 
[70,71]. Binding of muraymycin D2 to the MraY active site does not involve the catalytic Asp 25 
residues and does not require Mg2+, but several other binding interactions were elucidated [76]. The 26 
uracil base is bound via stacking interactions to Phe-262 (see Figure 9A), as well as hydrogen-27 
bonding interactions to the uracil carbonyl and NH groups. The amino group of the aminoribose 28 
moiety is bound by Asp-193, whose mutation greatly reduces affinity for muraymycin D2, and 29 
Asn-190. The strong binding of the  amino group of the aminoribose helps to rationalise why this 30 
group is important for activity in several nucleoside antibiotics [39,73]. The carboxyl terminus of 31 
the peptide chain is bound by Gln-305, a residue that is conserved in bacterial MraY homologues, 32 
and the  epi-capreomycidine amino acid is bound by His-324 and His-325 [76]. 33 
 34 
 13 
 1 
Figure 8. Structures of A. aeolicus MraY (A) containing no ligand, (B) complexed with 2 
muraymycin D2, showing active site residues (A) and conformational change upon muraymycin 3 
binding (B). 4 
 5 
 In 2017 the structure of a complex of Clostridium boltae MraY with tunicamycin was 6 
published [77]. The overall conformation of the protein was similar to the MraY-muraymycin 7 
complex, but some similarities and differences in the enzyme-ligand binding interactions were 8 
observed [77,78]. As in the MraY-muraymycin complex, the uracil base was bound in a small 9 
cavity, interacting via stacking interactions to Phe-228 (see Figure 9B), and the 4-carbonyl 10 
group binding to Asn-221. The HHH motif (His-290, His-291) are also involved in ligand binding, 11 
in this case to the GlcNAc 4’- and 6’-hydroxyl groups. However, unlike the MraY-muraymycin 12 
complex, tunicamycin was found to interact with the catalytic Asp residues, with the tunicamine 9’-13 
hydroxyl group interacting with Asp-231, but in the absence of Mg2+ [77]. The structure of 14 
tunicamycin bound to its eukaryotic target enzyme GlcNAc-1-phosphate transferase involved in N-15 
linked glycoprotein biosynthesis was also reported in 2018, showing some differences in active site 16 
binding, compared to MraY [79]. 17 
 Hence both nucleosides bind to an MraY structure that has undergone a conformational 18 
change, both show specific binding for the uracil base and some involvement of the HHH motif in 19 
ligand binding, but muraymycin and tunicamycin show different polar contacts in the MraY active 20 
site [78].  21 
 14 
 1 
 Figure 9. Structures of MraY-ligand complexes, showing the location of selected binding 2 
interactions. A.  A. aeolicus MraY complexed with muraymycin D2. B. C. boltae MraY complexed 3 
with tunicamycin. 4 
 5 
 15 
2.3  Interaction with protein-protein interaction site for bacteriophage lysis protein E 1 
 E. coli MraY is also targetted by an antibacterial lysis protein E from bacteriophage X174, 2 
which interacts with Phe-288 and Glu-287 of MraY, on the exterior face of transmembrane 9 of 3 
MraY, via an Arg-Trp-x-x-Trp sequence motif near the N-terminus of the E protein [80]. The 4 
presence of a guanidine-containing amino acid epi-capreomycidine in muraymycin, and two 5 
aromatic residues (Trp or m-Tyr and a second m-Tyr) in the mureidomycin/pacidamycin structures, 6 
is reminiscent of this Arg-Trp-x-x-Trp motif. Rodolis et al have shown that pacidamycin 1 and a 7 
synthetic muraymycin analogue showed significantly reduced activity against site-directed F288L 8 
and E287A MraY mutant enzymes [81], suggesting that parts of the antibiotic structure somehow 9 
aid the targetting of MraY in vivo, perhaps aiding uptake into the cell via a hydrophobic channel 10 
present in the structure of MraY [75], as shown in Figure 10. This hypothesis might explain how 11 
these agents of molecular weight 600-1200 Da are able to access the MraY active site on the inner 12 
face of the cytoplasmic membrane, and also why it has proved difficult to design small analogues of 13 
these nucleoside antibiotics that retain both MraY inhibition and antimicrobial activity. 14 
 15 
Figure 10. Interaction with the E protein binding site in MraY (Phe-288 and Glu-287) by nucleoside 16 
antibiotics, and hypothesis for uptake to the MraY active site. 17 
 18 
 16 
 1 
3. Inhibition of other bacterial phospho-nucleotide transferase enzymes by nucleoside natural 2 
product analogues. 3 
There are homologues of MraY involved in lipid-linked cycles responsible for the 4 
biosynthesis of enterobacterial common antigen and O-antigen lipopolysaccharide (LPS) in Gram-5 
negative bacteria (WecA) [82], and teichoic acid in Gram-positive bacteria (TagO), both of which 6 
are integral membrane proteins that utilise UDP-GlcNAc and undecaprenyl phosphate as substrates 7 
[83]. CPZEN-45, a semisynthetic caprazamycin derivative undergoing clinical trials for treatment 8 
of tuberculosis, was found to inhibit transferase WecA in M. tuberculosis >20 fold more strongly 9 
than MraY, and CPZEN-45 also inhibits B. subtilis TagO 8-fold more tightly than B. subtilis MraY 10 
[43]. Selective synthetic inhibitors for TagO have also been published, based on the existing drug 11 
ticlopidine [84]. In contrast, the muraymycin analogues prepared by Tanino et al were highly 12 
selective for MraY inhibition over E. coli WecA [51], as were the dihydrosansanmycin analogues 13 
of Tan et al [24].  14 
A homologue of WecA (GacO) has been found to catalyse the formation of undecaprenyl-15 
diphospho-GlcNAc in the biosynthesis of the Lancefield group A carbohydrate in Streptococcus 16 
pyogenes [85]. A further group of small 20-25 kDa phospho-sugar transferase enzymes utilising a 17 
UDP-di-N-acetyl-bacillosamine substrate are involved in N-glycoconjugate biosynthesis in 18 
Campylobacter jejuni [86]. Synthetic peptidyl-uridine inhibitors have been synthesised as inhibitors 19 
of C. jejuni PglC, with IC50 values in the range 40-250 µM [87]. 20 
 21 
In conclusion, Nature produces several classes of uridine-based nucleoside antibiotics that 22 
target translocase MraY in the bacterial peptidoglycan biosynthetic pathway. Total synthesis of 23 
modified nucleoside analogues, and exploitation of the biosynthetic machinery for these natural 24 
products, offer considerable promise for the development of highly active antimicrobial agents to 25 
treat antibiotic-resistant infections. Understanding of the MraY structure will aid the development  26 
of selective MraY inhibitors, and the discovery of MraY homologues such as WecA and TagO has 27 
identified further interesting targets for antibacterial drug discovery by nucleoside analogues. 28 
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